Transforming the care of hypertrophic cardiomyopathy and related conditions.

[data-wf-bgvideo-fallback-img] { display: none; } @media (prefers-reduced-motion: reduce) { [data-wf-bgvideo-fallback-img] { position: absolute; z-index: -100; display: inline-block; height: 100%; width: 100%; object-fit: cover; } }

We seek to deliver better outcomes and quality of life for patients.

[data-wf-bgvideo-fallback-img] { display: none; } @media (prefers-reduced-motion: reduce) { [data-wf-bgvideo-fallback-img] { position: absolute; z-index: -100; display: inline-block; height: 100%; width: 100%; object-fit: cover; } }

Our Science

01

Our Approach

Our Approach

Our Approach

Overactive myosin plays a key role in hypertrophic cardiomyopathy. Our approach is to selectively address this underlying mechanism to improve heart performance.

02

About HCM

About HCM

About HCM

Hypertrophic cardiomyopathy (HCM) is among the most common rare diseases, affecting approximately 1 in 500 individuals in the United States.

‍

In HCM, the heart contracts with excessive force, causing the heart muscle to become abnormally thick, particularly in the left ventricle—the heart's main pumping chamber.

03

Pipeline

Pipeline

Pipeline

We are advancing our investigational treatment through global late-stage clinical development.

News & Updates

Braveheart secures $185M to advance challenger to Bristol Myers heart drug

November 5, 2025

Cardio biotech Braveheart gets $185M, names Biogen CEO as its chair

November 5, 2025

Braveheart Bio launches with mission to conquer heart disease market, capturing $185M series A

November 5, 2025

[data-wf-bgvideo-fallback-img] { display: none; } @media (prefers-reduced-motion: reduce) { [data-wf-bgvideo-fallback-img] { position: absolute; z-index: -100; display: inline-block; height: 100%; width: 100%; object-fit: cover; } }

Interested in joining our team?

Learn more about our openings.